CA-ACCELERATED-BIOSCIEN
4.5.2022 12:08:08 CEST | Business Wire | Press release
Accelerated Biosciences, a regenerative medicine innovator of proprietary human trophoblast stem cells (hTSCs), announced an agreement for Pluristyx, Inc., an advanced therapy tools and services biotechnology company, to provide iPSCs derived from hTSCs procured under Good Tissue Practices (GTP) for research evaluation.
Finding the ideal source of stem cells remains a challenge in cell and gene therapy. hTSCs overcome these challenges as they are ethically sourced, scalable, immune-privileged, pathogen-free, and chromosomally stable even at high population doublings. As Accelerated Biosciences’ CDMO partner, Pluristyx reprogrammed hTSCs to iPSCs with a footprint-free, proprietary mRNA method that yields highly pure stem cells with demonstrated capacity to form all three tissue types, including terminal differentiation into NK cells with superior cytolytic activity. hTSC-iPSCs are available in Pluristyx’s unique Ready-to-Differentiate® format (RTD®), allowing for rapid evaluation by eliminating the need for expansion out of thaw. Because hTSC-iPSCs are sourced under GTP, commercial partners can transition to a clinical-grade version when appropriate.
“We are thrilled to present our hTSC-iPSC platform as a new starting cell source for therapeutic companies. Our platform provides all of the business advantages and reduced risks. Clinical grade hTSC-iPSCs will be available in 2023 with a complete regulatory support package,” said Yuta Lee, Chief Executive Officer of Accelerated Biosciences.
“Pluristyx is excited to offer iPSCs derived from Accelerated Biosciences’ unique hTSC starting material. These iPSCs robustly form differentiated cells from all three lineages and are derived under GTP and they are not associated with any living human or embryo, making them an exceptional starting material for next generation cell-based therapies. Available in our RTD® format, interested groups can accelerate their internal evaluation and rapidly transition to a clinical-grade version suitable for therapeutic manufacturing,” said Benjamin Fryer, Chief Executive Officer of Pluristyx.
About Accelerated Biosciences
Accelerated Biosciences is a private regenerative medicine company commercializing the hTSC platform, discovered by physician and researcher, Professor Jau-Nan Lee, MB, MD, PhD. Accelerated Biosciences holds a proprietary source of hTSCs with a robust intellectual property estate. Accelerated Biosciences’ mission is to leverage its renewable, immune-privileged human cell source to accelerate cures to patients and to make gene and cell therapy affordable to all in need. For more information about Accelerated Biosciences, visit www.acceleratedbio.com or email mmolsbergen@c14consultinggroup.com .
About Pluristyx
Pluristyx is a privately held biotechnology company offering consulting, wet-lab and GMP banking services, and pluripotent stem cell products to support novel therapeutic developers. Pluristyx helps industry and academic researchers solve manufacturing and analytical challenges in cryopreservation, drug development, regenerative medicine, and cell and gene therapy. The Pluristyx team has decades of experience supporting every stage of cell therapy product development, from cell banking to drug product manufacturing including analytical testing and release of clinical grade cell therapy products. For more information about Pluristyx, visit www.pluristyx.com or email Kaye Reiter, PhD, JD at kreiter@pluristyx.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220504005149/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Grafana Labs Charts the Path to Agentic Operations with Watchers, Pages, and Agent Observability at ObservabilityCON 202620.10.2026 19:00:00 CEST | Press release
Grafana Labs delivers AI for observability and observability for AI: always-on agents to operate systems, and OpenTelemetry-native visibility into the agents you ship Grafana Labs, the company behind the open agentic observability cloud, today announced new releases at ObservabilityCON 2026 that move Grafana Cloud towards agentic operations, including the general availability of Agent Observability with OpenTelemetry support and of Assistant Watchers, and previews of Grafana Pages and Grafana Managed Sandboxes. As AI moves into production, teams face two connected challenges: using agents to operate their systems and understanding the behavior of the agents themselves. In the 2026 State of Observability Report, also released this week by Grafana Labs and ETR, a Futurum company, 68% of the 300 IT and engineering leaders surveyed have moved AI for observability past investigation into pilots or production. But confidence depends on the task and readiness varies: 85% report comfort with r
Grafana Labs Brings Faster Full-text Search and Smarter Data Optimization to Grafana Cloud at ObservabilityCON 202620.10.2026 19:00:00 CEST | Press release
Adaptive Logs Archive lets teams keep more logs for less, and faster queries for rare values in Grafana Cloud Logs help them, and their agents, find what matters in seconds Grafana Labs, the company behind the open agentic observability cloud, today announced new releases at ObservabilityCON 2026 that help teams manage their telemetry in the AI era, finding the right log line in seconds and keeping only the telemetry worth paying for as AI workloads scale. Major query performance enhancements to Grafana Cloud Logs, built on technology from the company's Logline acquisition, are now generally available, and Adaptive Logs Archive is in public preview. AI is massively increasing telemetry volumes. Coding agents are turning everyone into a developer, so more software is being built, faster, and all of it needs to be watched. The agents add to the load too, since every agent call and tool call emits its own telemetry. Left alone, observability costs grow with every new workload, which makes
Nissan Technical Centre Europe Adopts Sonatus Fastlane™ Platform to Accelerate Vehicle Test and Validation20.10.2026 18:37:00 CEST | Press release
Event-driven data collection and AI-powered root-cause analysis to become standard practice for new NTCE vehicle programs; Proven to cut investigation time from two weeks to two days Following a successful proof of concept and ongoing engineering development over the past 12 months, Nissan Technical Centre Europe (NTCE), Nissan’s primary R&D hub for its global regions, is expanding its use of the Sonatus® Fastlane™ Platform across its pre-start-of-production (SOP) validation workflow. The platform’s event-driven data collection and root-cause analysis have reduced the time NTCE engineers spend investigating vehicle software issues from two weeks to two days. NTCE plans to make the platform a standard part of validating future vehicle programs, including upcoming models such as the Nissan JUKE. With the Fastlane Platform, engineers have the data they need from the moment a fault occurs. Teams deploy targeted data-collection policies from the cloud, and capture begins automatically when
FlightSafety International and Honda Aircraft Company Partner to Offer New Course to HA-420 Pilots20.10.2026 18:00:00 CEST | Press release
Expanded collaboration brings advanced runway safety training to HondaJet pilots FlightSafety International Inc. (FSI), the global leader in aviation training and simulation technology, today announced an expansion of its longstanding partnership with Honda Aircraft Company to provide a new Runway Operations Mastery course for HA-420 Elite and Elite II pilots. Developed in collaboration with Honda Aircraft Company, the immersive training course focuses on strengthening pilot proficiency to support safer operations. The new voluntary offering reflects the companies’ shared commitment to advancing aviation safety through specialized training. “For more than 75 years, FlightSafety’s mission has been to advance aviation safety through training that addresses real-world challenges pilots face,” said Ben Carter, Executive Vice President, Learning Center Operations, FlightSafety International. “This new course reflects our ongoing commitment to working with our OEM partners to deliver special
TRU Simulation introduces first Cessna Grand Caravan EX Flight Training Device on the Veris platform20.10.2026 17:00:00 CEST | Press release
The Cessna Grand Caravan EX Veris provides a high-fidelity, cost-effective solution for pilot development and expands training opportunities for one of the world’s most widely operated utility aircraft TRU Simulation + Training Inc., a Textron Inc. (NYSE:TXT) company, and an affiliate of Textron Aviation Inc., announced today the introduction of its Cessna Grand Caravan EX Veris Virtual Reality Flight Training Device (FTD), expanding the Veris product line to support one of the aviation industry's most versatile and widely utilized aircraft platforms. The announcement marks the first Caravan-configured training device offered within TRU Simulation's portfolio and reflects the company's continued investment in immersive aviation training technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261020834162/en/ TRU Simulation introduces first Cessna Grand Caravan EX Flight Training Device on the Veris platform "The Veris p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom